AbbVie (ABBV) AGM 2025 summary

Opening remarks and agenda

• Chairman welcomed shareholders and introduced board and executive management, noting the upcoming transition of the chair role in July 2025.

• Five business items were presented: election of directors, auditor ratification, advisory vote on executive compensation, management proposal to eliminate supermajority voting, and a shareholder proposal.

Financial performance review

• 2024 net revenues reached $56.3 billion, exceeding expectations by over $2 billion.

• Adjusted EPS was $10.12, $0.49 above initial guidance midpoint.

• Achieved rapid return to sales growth after Humira's U.S. loss of exclusivity, with growth platform delivering over 18% sales growth.

• Increased adjusted R&D investment by $3 billion and executed strategic transactions, including ImmunoGen and Cerevel acquisitions.

Board and executive committee updates

• Announced succession plan: CEO Robert Michael to become Chairman in July 2025 as current Chairman retires.